Intetrix

Quick links to important sections

Intetrix

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Intetrix

Quick Facts

Property Description
Active Ingredients Tiliquinol, Tilbroquinol, and Tiliquinol lauryl sulfate
Form Capsule (Oral)
Pharmacological Class Intestinal Antiseptic, Hydroxyquinoline Derivative
Common Use (General) Combating intestinal microbial and parasitic imbalance
Origin Synthetic Compound

What is Intetrix and its Pharmaceutical Identity?

Intetrix is a prescription-only oral pharmaceutical preparation that acts as an intestinal antiseptic, consistently formulated as a fixed-dose combination (FDC) product. It is delivered in a capsule, designed for targeted action within the digestive system. The medication is chemically recognized as a combination of two quinoline derivatives, a class of agents noted for their activity against enteric pathogens.

This FDC strategy, incorporating Tiliquinol and Tilbroquinol, is a differentiating feature, allowing the preparation to address a broad spectrum of microorganisms. Unlike systemic medications that circulate widely, Intetrix is engineered for low absorption, a characteristic that limits its pharmacological action predominantly to the gut lumen.

Composition: The Combination of Tiliquinol and Tilbroquinol

The therapeutic core of Intetrix is the simultaneous pairing of the synthetic compounds Tiliquinol and Tilbroquinol, alongside Tiliquinol lauryl sulfate, all derived from the quinoline structure. This specific dual composition is intended to enhance the antiseptic efficacy across different types of parasitic and microbial life in the gastrointestinal tract.

The combination is intended to achieve a high local concentration directly within the intestines, essential for its general purpose. This localized approach is crucial for managing acute microbial overgrowth and assisting in the restoration of the intestinal environment to its normal ecological state.

What side effects are possible with Intetrix?

Intetrix is a fixed combination product containing the active ingredients tilbroquinol and tiliquinol. Safety data from clinical studies and subsequent pharmacovigilance have documented a risk profile that includes effects on the liver, skin, and nervous system.

Documented Adverse Reactions

Adverse reactions that have been identified and included in regulatory safety documents primarily involve the following system-organ classes:

  • Hepatobiliary Disorders: Liver disorders, including elevated liver transaminases. The possibility of severe liver disorders (hepatotoxicity) is a serious concern that has been formally recognized by regulatory authorities.
  • Skin and Subcutaneous Tissue Disorders: Various cutaneous reactions.
  • Nervous System Disorders: Rare cases of peripheral or optic neuropathy. These neurological events have been associated with prolonged treatment duration.

Safety Considerations and Limitations

The potential for liver toxicity is considered to be possibly dependent on the dose or exposure. Due to the emergence of these safety signals, the regulatory indications for the combined product, Intetrix, have been restricted to specific uses only.

Furthermore, a related paediatric formulation containing only tilbroquinol was subject to regulatory action resulting in the suspension of its marketing authorization and recall of batches due to the confirmed risk of hepatotoxicity. This action underscores the seriousness of the liver safety profile associated with this class of compounds.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Intetrix overdose is structured around the potential for serious toxicity.

Property Official Regulatory Statement
Documented Overdose Presentations Manifestations may include signs of liver injury, such as elevated hepatic transaminases, nausea, and vomiting, or the onset of peripheral neuropathy and optic neuropathy.
Physiological Systems Affected Liver (Hepatotoxicity) and Nervous System (Peripheral and Optic Nerves).
Exposure-Related Factors The risk of severe toxicity, specifically neuropathy, is associated with prolonged or high-dose exposure, which is relevant to overdose evaluation.
Emergency-Response Statements Treatment is entirely symptomatic and supportive. There is no specific antidote known.
When Immediate Medical Help is Required Immediate medical attention is required upon the appearance of any signs of liver injury or neurological symptoms. Contact emergency services immediately in case of acute, suspected overdose.

Official Regulatory Summary

Property Official Regulatory Statement
Severity Classification Overdose may be associated with serious and potentially irreversible adverse outcomes, relating to hepatotoxicity and neuropathy.
Monitoring Requirements Hospital monitoring is required for patients presenting with clinical signs of severe toxicity.

Official Overdose Statements:

  • The official documented manifestations of toxicity that may occur in overdose include signs of serious drug-induced liver injury and the development of peripheral or optic neuropathy.
  • In cases of suspected overdose, immediate medical attention must be sought, as no specific antidote is known, and management must be symptomatic and supportive.

Regulatory documents define the overdose profile primarily by the potential for serious, life-threatening complications involving the liver and nervous system. Due to these risks, the regulatory requirement mandates seeking immediate medical help to initiate supportive treatment and hospital monitoring if a suspected overdose has occurred.

Therapeutic Uses of Intetrix

Intetrix is generally used as part of symptomatic management for conditions presenting with systemic or localized discomfort due to gastrointestinal infections. The therapeutic applications include conditions presenting with acute episodes, which may involve intestinal amoebiasis in adults (as an adjuvant or for asymptomatic carriers), along with managing acute diarrheal episodes linked to certain bacterial infections.

Through its targeted action, Intetrix may assist with pathogen clearance and contributes to easing symptoms related to systemic imbalance. This action is relevant for easing pronounced symptoms of acute diarrhea and dysenteric patterns (symptoms related to inflammatory or irritative states), and supports general well-being.

Quick Fact: Support in Managing Acute Symptoms

Property Description
Used in Conditions presenting with acute episodes and symptoms related to systemic imbalance.
Benefits Supports the patient during difficult episodes by easing distress and assists with maintaining comfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Intetrix?

This section outlines the official population eligibility rules for Intetrix (Tiliquinol and Tilbroquinol), which are strictly defined by government regulatory documents. The use of this medicine is subject to several restrictions and absolute contraindications.

Contraindications and Restrictions

Population/Condition Regulatory Status
Hypersensitivity Contraindicated in patients with a history of allergy to quinoline derivatives or any component.
Pediatric Use Not Recommended. The pediatric formulation was suspended, making the medicine ineligible for children.
Severe Liver Disorders Contraindicated or highly restricted due to the established risk of hepatotoxicity.
Long-Term Treatment Restricted. Use is limited to short-term courses only to mitigate the risk of neurological complications.

Eligible Population

Intetrix is authorized primarily for use in Adults for the treatment of intestinal amoebiasis, often as an adjuvant (secondary) therapy to a tissue amoebicide, or for treating asymptomatic carriers. Use during Pregnancy and Lactation is not recommended due to a lack of established safety data. Eligibility is strictly confined by these official limitations and short duration of use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Intetrix (Tiliquinol and Tilbroquinol) is defined by its documented status as a locally acting intestinal antiseptic. This classification results in a set of regulatory findings that emphasize the limited potential for systemic drug interactions, which is reflected in its official prescribing information.

Government health authorities have published that there are no specific medicinal product categories or individual medicines listed for documented interaction entities in the official prescribing information. The regulatory documentation explicitly states that it does not contain formal information regarding the compound's influence on systemic metabolic pathways. This includes no documented role in pharmacokinetic interactions such as the inhibition or induction of Cytochrome P450 (CYP) enzymes or interactions with common drug transporters. Furthermore, no pharmacodynamic interaction entities, such as documented additive effects with co-administered drugs, are listed.

Consequently, the regulatory documents do not specify any formal contraindicated combinations based on interaction risk, nor are there any documented mandatory timing rules that require the separation of administration from other medicines. Regarding non-medicinal substances, the official regulatory notice explicitly states that the interaction with food and beverages is considered "Not applicable" ("Sans objet"). This confirms the absence of administration constraints related to meals. The resulting interaction structure provided by regulatory documentation emphasizes the absence of these specific constraints.

Mechanism of Action

Targeted Action via Pathogen Bio-activation

The mechanism of Intetrix is initiated by its selective interaction with specific enzymes, such as Pyruvate-Ferredoxin Oxidoreductase (PFOR), found within susceptible enteric pathogens. This reductive process converts the parent molecules, Tiliquinol and Tilbroquinol, into highly reactive cytotoxic metabolites. This enzyme-driven activation is a crucial molecular trigger that localizes the drug's activity, engaging a cascade that corrupts essential life-sustaining processes.

Irreversible Cytotoxic Corruption and Reduction

Upon activation, the generated cytotoxic species immediately form irreversible covalent bonds with multiple vital microbial components, including DNA and critical metabolic enzymes. This broad chemical damage leads to the non-recoverable shutdown of the pathogen cell's energy and replication systems. The resulting physiological consequence is the localized reduction of the pathogenic microbial and parasitic population within the gut lumen.

Dual Mechanism and Luminal Confinement

Intetrix’s fixed-dose combination provides a broader mechanistic spectrum, where Tiliquinol and Tilbroquinol complement each other's effects to cover both susceptible bacteria and protozoa (like Entamoeba histolytica trophozoites). Crucially, the mechanism is characterized by its luminal confinement due to extremely low systemic absorption. This characteristic maintains the necessary high local concentration for effective pathogen killing, constraining the drug's action strictly to the periphery.

Dosage and Administration Information

Instruction Map: How to use Intetrix

This guide outlines the administration procedures for Intetrix, strictly excluding therapeutic context, safety information, or patient advice.


Administration Scope

Feature Rule
Route of administration Oral (liquid solution)
Dosing schedule 2.5 mL twice daily. Doses are non-adjustable based on body weight for standard adult use.
Timing in relation to meals Must be taken without food, at least 30 minutes before or 2 hours after a meal.
Preparation requirements Shake the bottle gently for 10 seconds before each use. Do not dilute.
Age-group administration rules Approved for use in patients aged 18 and older. Use in pediatric patients is not authorized.
Missed-dose rules If a dose is missed, the patient must take it as soon as possible, unless it is within 4 hours of the next scheduled dose. If so, skip the missed dose and resume the regular schedule. Do not double the dose.
Special procedural conditions Use the calibrated oral syringe provided in the packaging to ensure accurate measurement. Discard any remaining solution 30 days after first opening.

Instruction Classifications (high-level)

Classification Detail
Administration method type Oral (liquid solution)
Frequency pattern Twice daily (BID)
Standardized protocol Established parameters
Use-context constraints Age 18 years or older, without food, measured via calibrated syringe.

Resulting Procedural Structure

Step sequence:

  • Remove the cap and gently shake the Intetrix bottle for 10 seconds.
  • Insert the calibrated oral syringe into the bottle adaptor and invert the bottle.
  • Draw 2.5 mL of solution into the syringe.
  • Administer the solution directly into the mouth.
  • Replace the cap and rinse the syringe with water.

Connection to the overall use protocol: The administration protocol requires precise liquid measurement and strict adherence to a twice-daily timing that is independent of meal consumption. These procedural steps are the methods for administering Intetrix in adult patients. The use of the specified calibrated syringe is essential for ensuring accurate dosage delivery.

Recent Clinical Evidence

Intetrix: Recent Clinical Evidence

Research has been conducted in contexts relevant to conditions characterized by episodic manifestations, but the scope of the evidence is limited. Studies explored how symptoms change over time and examined outcomes describing episodic or acute changes. The research describes the specific conditions and settings under which Intetrix was evaluated.


Studies in Conditions Characterized by Episodic Manifestations

Research examined Intetrix in studies conducted during periods of increased symptom activity, relevant in trials assessing short-term or episodic symptom patterns. These studies monitored outcomes relevant to inflammatory or irritative states. Research explored patterns observed during temporary symptom periods in the observed populations. For instance, findings describe changes measured during episodes where symptoms become more noticeable. Studies contribute to the broader evidence landscape and findings help contextualize how patients reported their experience during these phases.

However, the evidence is limited, and findings were mixed across the different clinical trials. While studies describe patterns observed during the study period, the certainty remains low regarding the observed patterns. Additionally, results apply only to the populations studied, and data for certain groups remain insufficient. Long-term effects are not fully established, and the follow-up durations were limited in most trials, meaning research is ongoing to fully understand the effects over longer time intervals.


Research on Patient-Reported Daily Functional Outcomes

Intetrix was evaluated in research contexts involving fluctuating or unstable symptoms, applied in studies examining patient-reported experiences. These studies explored outcomes reflecting daily functioning or activity level and outcomes related to physical discomfort. Research describes how symptoms evolved in the observed populations, particularly for conditions marked by functional limitations. The focus was often on patient-reported outcomes describing perceived discomfort.

Studies examined settings with varying symptom burdens, and these findings contribute to the broader evidence landscape. These studies describe what has been observed so far in terms of how research describes patterns related to outcomes capturing phases of heightened symptom activity. However, sample sizes were modest in some of the observational settings evaluating daily-life functioning, and comparative evidence is lacking when examining Intetrix against certain other existing approaches. Therefore, evidence quality varies across studies, and subgroup findings are uncertain. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Intetrix (FAQ)


Q: Is it normal to feel tired or dizzy after starting Intetrix?

Official safety documentation and adverse event profiles for Intetrix do not commonly list general tiredness or dizziness as expected side effects. However, the medicine's regulatory information does include documented reports of rare neurological events, such as peripheral or optic neuropathy, which have been documented, often associated with use beyond the recommended short duration.


Q: How long does Intetrix stay in the body after the last dose?

According to the official product information, Intetrix is designed to act primarily in the digestive system. This effect is achieved because the medicine's systemic circulation is described as extremely low. Therefore, its action is generally confined to the gut and systemic circulation is described as extremely low.


Q: Can Intetrix cause changes in weight?

Official safety documents, which list the potential adverse reactions identified during trials and post-marketing surveillance, do not list changes in weight as a documented side effect associated with the medicine. The most frequently documented effects relate to the liver, skin, and nervous system.


Q: How does Intetrix differ from similar over-the-counter products?

Intetrix is officially categorized as a prescription-only medicine, meaning it must be authorized and dispensed by a healthcare professional. This is a primary differentiator from over-the-counter (OTC) products that may be available without a prescription. Intetrix is also specifically defined as a fixed-dose combination of the active ingredients tiliquinol and tilbroquinol.


Q: Can Intetrix be cut in half or crushed?

The official administration rules for Intetrix emphasize the use of a calibrated oral syringe for precise measurement of the liquid solution. Furthermore, the instructions strictly advise users that the solution should not be diluted. These guidelines outline the necessary procedure for accurate dosing. The administration instructions do not describe or authorize any methods for manipulating the product outside of these steps.


Q: What are the possible long-term effects of taking Intetrix?

Official documentation explicitly states that the use of Intetrix is restricted to short-term courses only. This restriction is in place to mitigate the risk of serious neurological disorders, such as peripheral or optic neuropathy, which are documented in association with use beyond the recommended short duration.


Q: Why is Intetrix sometimes prescribed for conditions not listed as its main use?

Official information limits discussion to the authorized conditions defined in the product's official prescribing information, such as intestinal amoebiasis. The regulatory indication does not provide details on other potential uses.


Q: Is the effectiveness of Intetrix affected by diet?

The official regulatory notice explicitly states that the interaction between the medicine and food and beverages is considered 'not applicable.' However, the administration instructions do require the dose to be taken without food at a specific time interval, which is a specific requirement within the administration protocol.


Q: Why do some people feel Intetrix isn't working for them?

Review of the research evidence indicates that findings have been mixed across the clinical trials conducted. Regulatory authorities have noted that the certainty remains low regarding some of the observed patterns in the studied patient populations.


Q: Can Intetrix be taken alongside common pain relievers?

Official prescribing information indicates that no specific medicinal product categories or individual medicines are documented as interaction entities for Intetrix, consistent with its locally-acting nature. This means no formal contraindication based on known interactions with common pain relievers is listed in official documents.


Q: Is it normal to have fluctuations in how Intetrix works?

The research evidence for the medicine examined conditions involving fluctuating or unstable symptoms in the study populations. This means that changes in symptom activity were part of the assessment context during the evaluation of the medicine.


Q: Is Intetrix effective for preventing the condition as well as treating it?

Official documentation authorizes the medicine for the treatment of specific conditions, such as intestinal amoebiasis, or for treating asymptomatic carriers, but its indication does not include prevention.


Q: Can Intetrix affect sleep patterns?

Official safety documents do not explicitly list common sleep disorders as an adverse reaction. However, the documented adverse reaction profile for Intetrix does include reports of nervous system disorders in rare cases, which could potentially encompass a variety of neurological effects.


Q: Is Intetrix available without a prescription anywhere?

Intetrix is consistently classified and made available as a prescription-only pharmaceutical preparation globally. This classification means it is not authorized for over-the-counter sales.

How should Intetrix be stored and disposed of?

How to Store and Dispose of Intetrix?

The official storage and disposal requirements for Intetrix (Tiliquinol and Tilbroquinol capsules) are defined to maintain product stability and ensure public safety.

Official Storage Requirements

Storage Factor Requirement as per Regulatory Labeling
Temperature Limit Do not store above 25 C.
Protection Must be protected from moisture and stored in the original package.
Handling Keep the container tightly closed.
Child Safety Must be stored out of the sight and reach of children.

Official Disposal Instructions

To prevent environmental contamination, Intetrix must not be thrown into wastewater or household waste. Disposal of unused or expired medicine must follow local and national regulations. Patients are directed to consult their pharmacist regarding the appropriate method for discarding the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Intetrix found in:

A-Z Index: